Royal London Asset Management Ltd. Sells 75,224 Shares of Thermo Fisher Scientific Inc. $TMO

Royal London Asset Management Ltd. trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 433,314 shares of the medical research company’s stock after selling 75,224 shares during the period. Royal London Asset Management Ltd.’s holdings in Thermo Fisher Scientific were worth $217,246,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. Legacy Wealth Managment LLC ID increased its position in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the last quarter. Kilter Group LLC bought a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $25,000. Allied Private Wealth LLC purchased a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $26,000. High Note Wealth LLC raised its position in Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock worth $27,000 after acquiring an additional 29 shares during the period. Finally, Swiss RE Ltd. purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $28,000. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Piper Sandler boosted their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a report on Monday, July 27th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Finally, Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock valued at $44,122,820 over the last 90 days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.4%

Thermo Fisher Scientific stock opened at $621.87 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $647.00. The firm’s 50 day moving average price is $558.64 and its 200-day moving average price is $512.08. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock has a market cap of $229.94 billion, a P/E ratio of 33.45, a PEG ratio of 2.57 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period last year, the company posted $4.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.